National and Kapodistrian University of Athens
Διερεύνηση του τρόπου παραγωγής και δράσης πεπτιδικών θραυσμάτων της προθυμοσίνης α: νέα ανοσοενισχυτικά μόρια των λεμφοκυτταρικών αποκρίσεων
Abstract
dc:descriptionProthymosin α (proTα) was initially isolated from rat thymus in 1984. It is, inprinciple, a nuclear protein with a distinctive dual role. Intracellularly, it participates in the regulation of cell proliferation and cell death, while extracellularly proTα acts pleiotropically, inducing and enhancing immune responses. In the frame of its immunomodulatory role, both the intact molecule and its carboxyterminal immunoreactive peptide proTα(100-109) induce the phenotypic maturation of dendriticcells, which comprise the professional antigen-presenting cells of the immune system.The purpose of the present PhD thesis was the investigation of the ability of proTα and proTα(100-109) to act as adjuvants via activating dendritic cells, focusing on:V. The identification of the surface binding site(s)/receptor(s) and the intracellular proteins that are activated downstream there of and mediate the effect of proTα and proTα(100-109) on human dendritic cells, VI. The thorough analysis of the phenotype and functionality of the proTα- and proTα(100-109)-matured dendritic cells and the type of T cell responses that they induce in vitro,VII. The investigation of the anticancer activity of proTα and proTα(100-109) in an invivo melanoma model in mice and the ex vivo analysis of the proTα- and proTα(100-109)-induced immune responses, and VIII. The association of the two distinct roles (intracellular and extracellular) of proTα and the investigation of the possibility that the intact molecule and/or its immunoreactive decapeptide proTα(100-109) can act extracellularly as «dangersignals». First, taking into consideration recent data reporting that proTα signals through Toll-like receptors (TLRs) on human monocytes and binds to TLR-4 on murine macrophages, we sought to investigate whether the same receptor is also activated in human dendritic cells. Using flow cytometry, we studied TLR-4 surface expression on dendritic cells differentiated from human peripheral blood monocytes upon their maturation with LPS, proTα or proTα(100-109) for specific time intervals. We observed that all three maturation factors led to a similar transient increase of TLR-4 expressionon the dendritic cells’ surface. Using Western blot analysis, we also observed that the increased TLR-4 expression was accompanied by an analogous intracellular activation,since the expression levels of the TLR-4 adaptor proteins, MyD88, TIRAP and TRIF, werefound elevated upon stimulation with LPS, proTα or proTα(100-109). These data comprise the first evidence that the ability of proTα and proTα(100-109) to mature human dendritic cells, similarly to LPS, is at least partially mediated by TLR-4, downstream of which the MyD88- and TRIF-dependent signalling pathways are activated. Our next goal was to investigate whether dendritic cells that mature in the presence of proTα or proTα(100-109) express specific dendritic cell markers and produce T cell stimulating cytokines. In accordance with already published data, proTα and proTα(100-109) enhanced HLA-DR, CD11b, CD80, CD83, CD86 and CD40 surface expression on dendritic cells, to levels comparable to those achieved by LPS. These expression levels were also comparable to those induced in the presence of TNF-α, amaturation factor which has been widely used in dendritic cell-based clinical trials. Moreover, the analysis of dendritic cell culture supernatants showed that the proTα- and proTα(100-109)-matured dendritic cells, similarly to standard (LPS- or TNF-α-matured) dendritic cells, produced in principle the pro-inflammatory cytokine IL-12, indicatingtheir ability to promote ΤH1-type of immune responses.This ability was further verified by studying the functionality of these dendritic cells in vitro. In detail, proTα- and proTα(100-109)-matured dendritic cells were used to stimulate autologous T cells, both memory and naive, in the presence of viral and tumor derived peptide-antigens, respectively. The assessment of helper T cell cytokine production via multi-color flow cytometry in both experimental systems, revealed enhanced production of pro-inflammatory (TNF-α, IFN-γ, IL-2) and reduced productionof anti-inflammatory (IL-4, IL-5, IL-10, IL-13) cytokines, thus verifying the polarization toward ΤH1-type immune responses. The cytokine profile of CD8+ T cells was analogous, indicating their differentiation to TC1-type. More over, the tumor-specific cytotoxic T cells generated in the naive T cell stimulation cultures were polyfunctional and exhibitedan antigen-specific MHC class I-restricted cytotoxicity. Similarly, the generated tumor specific T cell lines exhibited an antigen-specific MHC class II-restricted proliferationability. In continuation to our in vitro results, we studied proTα’s and proTα(100-109)’sability to induce tumor-reactive immune responses in vivo in a melanoma model. For the development of mouse melanoma tumors, we used B16.F1 cells, as these cells are known to be antigenic, immunogenic and can form solid tumors when inoculated subcutaneously in syngeneic C57BL/6 mice. Both proTα and its immunoreactive peptide proTα(100-109) were administered to the animals in conjunction with B16.F1-derivedtumor peptide-antigens, eluted from the same cancer cell line and anticipated to trigger the generation of tumor-reactive immune responses in vivo. We developed two protocols, one of heterochronous and one of simultaneous administration of immunoenhancing factors and cancer cells. By recording the development of the tumors,we observed that administration of proTα and proTα(100-109) was beneficial, as itreduced tumor growth rates and prolonged the overall survival of the animals in both immunotherapeutic protocols. Of interest, ex vivo analysis of splenocytes isolated from selected animals of all groups verified that the observed inhibition of melanoma cell growth was attributed to the in vivo induction of tumor antigen-specific, as well as of non-specific immune responses, mediated by activated T and NK/LAK cells, respectively. According to the literature, intracellularly, proTα regulates cell proliferation and exerts an anti-apoptotic role. According to the findings of the present PhD thesis, the same polypeptide and its immunoreactive decapeptide proTα(100-109), extracellularly,enhance cell-mediated immune responses both in vitro and in vivo. In an attempt to link these two roles, we studied the conditions under which proTα(100-109) is producedand exocytosed in order to exert its extracellular role. It is already known that early during apoptosis, proTα is translocated to the cytoplasm, where it is truncated by activated caspases 3 and 7 at aminoacid (D) 99. ProTα’s fragment 1-99 has already been detected in the cytoplasm, while to date proTα(100-109) has not been intracellularly detected. Assuming that the decapeptide could be possibly released/excreted extracellularly, we first showed that proTα(100-109) remains intact and is not further cleaved by activated proteases during apoptosis. Further, the extracellular medium of apoptotic HeLa cells was collected and analyzed using RP-HPLC and mass spectrometry. In the mass spectras acquired, a peak corresponding to the theoretical molecular weight of proTα(100-109) was recorded, indicating that the decapeptide is exocytosed underapoptotic conditions, via an, as yet, unknown mechanism. Of interest, as we additionally showed, the extracellular release of proTα(100-109) is associated only with apoptosis and not with other types of cell death, such as necrosis or oncosis. In summary, in the present PhD thesis, we present significant data on the immunoenhancing activity of proTα and proTα(100-109). Studying the expression of TLR-4, as well as that of the intracellular proteins participating in signalling pathways downstream there of, we verified that this receptor is mediating, at least partially, the maturation of dendritic cells, induced by the two peptides. The proTα- and proTα(100-109)-matured dendritic cells express high levels of MHC class II and cost imulatory molecules and produce pro-inflammatory cytokines. The assessment of their functionality showed that, apart from phenotypically mature, these dendritic cells arealso functionally immunocompetent and can stimulate antigen-specific T cells in vitro, regardless of their cell type (memory and naive T cells) and/or the nature of the antigen(viral- and tumor-derived). The immune responses that they induce are mediated byTH1- and TC1-type Τ cells. In parallel, both intact proTα and its immunoreactive fragment proTα(100-109) enhanced, in principle, tumor-specific immune responses in an in vivo mouse melanoma model, leading to the reduction of tumor growth and the prolongation of the overall survival of the animals. Combining the afore presented datawith the first evidence for the specific exocytosis of proTα(100-109) under apoptotic conditions, the results of the present PhD thesis support the ability of proTα and proTα(100-109) to act as «danger signals», inducing and promoting immune responsesin vivο. If this hypothesis holds true, new perspectives are opened as for the potentialuse of the two peptides as adjuvants to improve, in principle, the efficacy of anticancer vaccines that are based on tumor antigens administered in conjunction with dendriticcells.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Ioannou, Kyriaki
- Ιωάννου, Κυριακή
Subjects
dc:subject × 20- Προθυμοσίνη α
- Ανοσοδραστικό δεκαπεπτίδιο
- Υποδοχείς τύπου-Toll
- Δενδριτικά κύτταρα
- Διέργεση λεμφοκυττάρων
- Ογκοειδική απόκριση
- Πρωτόκολλο ανοσοθεραπείας in vivo
- Ανάλυση σπληνοκυττάρων ex vivo
- Prothymosin a
- Immunoreactive decapeptide
- Toll-like receptors
- Dendritic cells
- Lymphocyte stimulation
- Tumor-specific response
- In vivo immunotherapeutic protocol
- Ex vivo splenocyte analysis
- Φυσικές Επιστήμες
- Βιολογία
- Natural Sciences
- Biological Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44264